• Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.41
+0 (0.00%)

This chart shows the closing price for MTCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Metacrine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTCR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Metacrine in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.41.

This chart shows the closing price for MTCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Metacrine.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2022HC WainwrightReiterated RatingNeutralLow
10/22/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$14.00 ➝ $2.00High
10/22/2021HC WainwrightDowngradeBuy ➝ NeutralHigh
10/22/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$2.50High
6/14/2021HC WainwrightInitiated CoverageBuy$15.00High
3/21/2021Royal Bank of CanadaReiterated RatingBuy$25.00High
12/1/2020HC WainwrightReiterated RatingBuyLow
10/12/2020Jefferies Financial GroupInitiated CoverageBuy$18.00High
10/12/2020Royal Bank of CanadaInitiated CoverageOutperform$25.00High
(Data available from 12/1/2017 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/2/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/1/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Metacrine logo
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.41
Low: $0.39
High: $0.44

50 Day Range

MA: $0.43
Low: $0.35
High: $0.50

52 Week Range

Now: $0.41
Low: $0.30
High: $1.73

Volume

96,252 shs

Average Volume

991,784 shs

Market Capitalization

$17.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Metacrine?

The following equities research analysts have issued stock ratings on Metacrine in the last twelve months: HC Wainwright.
View the latest analyst ratings for MTCR.

What is the current price target for Metacrine?

0 Wall Street analysts have set twelve-month price targets for Metacrine in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Metacrine in the next year.
View the latest price targets for MTCR.

What is the current consensus analyst rating for Metacrine?

Metacrine currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MTCR, but not buy more shares or sell existing shares.
View the latest ratings for MTCR.

What other companies compete with Metacrine?

How do I contact Metacrine's investor relations team?

Metacrine's physical mailing address is 3985 SORRENTO VALLEY BLVD. SUITE C, SAN DIEGO CA, 92121. The company's listed phone number is 858-369-7800 and its investor relations email address is [email protected] The official website for Metacrine is www.metacrine.com. Learn More about contacing Metacrine investor relations.